Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Telescope in Chile captures stunning new picture of a cosmic butterfly - 2Americans generally like wolves − except when we’re reminded of our politics
- 3Vote In favor of Your Favored Occasion Arranging Administration
- 45 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- 5Spain’s Picos de Europa: What to see and do in ‘the world’s most beautiful place’
- Spots To Go Birdwatching All over the Planet
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- Newly Identified ‘Lucy’s Hunter’ Was a 15-Foot Crocodile Lurking in Ancient Ethiopia
- 'The Boys' Season 5 premiere: How to watch for less, what to know about the final series and more
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
- Zendaya serves bridal-coded fashion with old, new and borrowed gowns for ‘The Drama’ press tour
- Three arrested in Paris after attempted bomb attack outside Bank of America
- Kenmore East reacts to their best overall delegation award at WNY Model United Nations General Assembly competition
